How This Evidence Evolved
Sepsis Recognition and Early Treatment
From SIRS to Sepsis-3
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
In-hospital mortality: 30.5% vs 46.5% (p=0.009) favouring EGDT
60-day mortality: no significant difference between EGDT, protocol-based, and usual care
90-day mortality: 18.6% vs 18.8% (p=0.90), no benefit of EGDT
90-day mortality: 29.5% vs 29.2% (p=0.90), no benefit of EGDT
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
Landmark Trials in This Story
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Established SIRS criteria and sepsis definitions used for 25 years
Early goal-directed therapy in the treatment of severe sepsis and septic shock
In-hospital mortality: 30.5% vs 46.5% (p=0.009) favouring EGDT
A randomized trial of protocol-based care for early septic shock
60-day mortality: no significant difference between EGDT, protocol-based, and usual care
Goal-directed resuscitation for patients with early septic shock
90-day mortality: 18.6% vs 18.8% (p=0.90), no benefit of EGDT
Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock
90-day mortality: 29.5% vs 29.2% (p=0.90), no benefit of EGDT
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Redefined sepsis using SOFA; introduced qSOFA for bedside screening
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3M+ peer-reviewed articles.